Abstracts tagged "corticosteroids"

Abstract Number: 803 • 2014 ACR/ARHP Annual Meeting
Corticosteroid-Related Adverse Events in Patients with Giant Cell Arteritis: A Claims-Based Analysis
Gordon H. Sun¹, Khaled Sarsour², Eunice Chang¹, Michael S. Broder¹, Neil Collinson³, Katie Tuckwell³, Pavel Napalkov² and Micki Klearman², ¹Partnership for Health Analytic Research, LLC, Beverly Hills, CA, ²Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, ³Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose Giant cell arteritis (GCA) is an inflammatory vasculitis preferentially affecting large and medium-sized arteries with an incidence of 1 to 30/100,000. High-dose oral corticosteroids…
Abstract Number: 492 • 2014 ACR/ARHP Annual Meeting
Patient-Reported Outcomes from a Canadian Study of Patients Taking Methotrexate and Etanercept
J. Carter Thorne¹, Edward C. Keystone², Janet E. Pope³, Melanie Poulin-Costello⁴, Krystene Phan-Chronis⁵ and Boulos Haraoui⁶, ¹Southlake Regional Health Centre, Newmarket, ON, Canada, ²Medicine, University of Toronto, Toronto, ON, Canada, ³St Joseph Health Care, London, ON, Canada, ⁴Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, ⁵Amgen Canada Inc., Mississauga, ON, Canada, ⁶Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose: The Canadian Methotrexate and Etanercept Outcome Study (CAMEO) evaluated etanercept (ETN) monotherapy vs ETN plus methotrexate (MTX) in biologic-naïve patients with rheumatoid arthritis…
Abstract Number: 295 • 2014 ACR/ARHP Annual Meeting
Intra-Articular Corticosteroid Injections in Juvenile Idiopathic Arthritis: Results from a UK Prospective Collaborative Study
Eileen Baildam¹, Roberto Carrasco², Susannah Holt³, Helen Foster⁴, Lucy R. Wedderburn⁵, Alice Chieng⁶, Joyce Davidson⁷, Yiannis Ioannou⁸, Kimme L. Hyrich⁹ and Wendy Thomson¹⁰, ¹Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ²Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Paediatric Palliative Care, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ⁴Newcastle University Medical School, Professor of Paediatric Rheumatology, Newcastle Upon Tyne, United Kingdom, ⁵Arthritis Research UK Centre for Adolescent Rheumatology,, UCL, UCLH, GOSH NHS Trust, London, United Kingdom, ⁶Paediatric Rheumatology, Royal Manchester Children's Hospital, Manchester, United Kingdom, ⁷Royal Hospital for Sick Children, Glasgow, United Kingdom, ⁸Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹⁰Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom
Background/Purpose Intra-articular corticosteroid injections (IACI) are a standard treatment in juvenile idiopathic arthritis (JIA). This study assessed response to IACI in a large prospective cohort…
Abstract Number: 240 • 2014 ACR/ARHP Annual Meeting
An Observational Study on the Influence of Glucocorticoid Exposure on Bone
Joseph Heath¹, Alexander Oldroyd², Maarten Boers³ and Marwan Bukhari², ¹Faculty of health and medicine, Lancaster University, Lancaster, United Kingdom, ²Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ³Dep of Epidemiology and Biostatistics, EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose It is well known that glucocorticoids are detrimental to bone health and has been postulated that their influence is more than their effect on…
Abstract Number: 2778 • 2014 ACR/ARHP Annual Meeting
Non-Systemic Vasculitic Neuropathy: Presentation, Therapeutic Management and Outcome
Benjamin Terrier¹, Fleur Cohen², Aude Rigolet³, Jean-Emmanuel Kahn⁴, Alice Berezne⁵, Olivier Benveniste⁶, Alain Créange⁷, Thierry Maisonobe⁸, Zahir Amoura⁹, Luc Mouthon¹⁰ and Loïc Guillevin for the French Vasculitis Study Group¹⁰, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²Internal Medicine, Pitié-Salpétrière, Paris, France, ³Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, ⁴Internal Medicine, Foch Hospital, Suresnes, France, ⁵Paris Descartes University, Internal Medicine department, Cochin Hospital, Paris, France, ⁶UMR 974, Sorbonne Universités, University Pierre et Marie-Curie-Paris 6, INSERM, Paris, France, ⁷Neurology, Henri Mondor, Créteil, France, ⁸Neuropathology, Pitie-Salpetriere Hospital, Paris, France, ⁹Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ¹⁰National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France
Background/Purpose Non-systemic vasculitic neuropathy (NSVN) is a small-to-medium–sized vessel vasculitis limited to the peripheral nervous system. It can be considered a single-organ vasculitis, as recently…
Abstract Number: 1857 • 2014 ACR/ARHP Annual Meeting
Determinants of Annual Healthcare Utilization and Overall Cost of Care in Individuals with Systemic Lupus Erythematosus in a Large Insurance Claims Database: Glucocorticoid Use
Shih-Yin Chen¹, Chan-Bum Choi^2,3,4, Qian Li⁵, Wei-Shi Yeh¹, Yuan-Chi Lee⁶, Amy H Kao¹ and Matthew H. Liang⁷, ¹Biogen Idec, Cambridge, MA, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Section of Rheumatology, VA Healthcare System, Boston, MA, ⁴Department of Aging, Brigham and Women's Hospital, Boston, MA, ⁵Evidera, Lexington, MA, ⁶Formerly of Evidera, Lexington, MA, ⁷Harvard Medical School, Boston, MA
Background/Purpose: Newer therapeutic agents in systemic lupus erythematosus (SLE) may increase cost of care but their effect on limiting the duration and the dosage of…
Abstract Number: 1397 • 2014 ACR/ARHP Annual Meeting
Impact of Corticosteroid Use on Remission Sustainability and Infection Rates Among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on a Real-World Canadian Population
Boulos Haraoui¹, Algis Jovaisas², William G. Bensen³, Rafat Faraawi⁴, John Kelsall⁵, Sanjay Dixit⁴, Jude Rodrigues⁶, Maqbool Sheriff⁷, Emmanouil Rampakakis⁸, John S. Sampalis⁸, Allen J Lehman⁹, Susan Otawa⁹, Francois Nantel¹⁰ and May Shawi¹⁰, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁶Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada
Background/Purpose The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…
Abstract Number: 1252 • 2014 ACR/ARHP Annual Meeting
Intravenous Methylprednisolone Pulse Therapy in Severe Inflammatory Eye Disease. a Multicenter Study
Montserrat Santos-Gómez¹, Emma Beltrán², Vanesa Calvo-Río¹, Ricardo Blanco¹, Norberto Ortego³, Jose L. García Serrano⁴, Lucía Martínez Costa⁴, Alejandro Fonollosa⁵, Marisa Hernández⁶, Elia Valls⁷, Félix Francisco⁸, Miguel A. Reyes⁹, Ignacio Torre Salaberri¹⁰, Olga Maíz¹¹, Ana Blanco¹², Santiago Muñoz-Fernández¹³, M. Mar Esteban¹⁴, Esperanza Pato¹⁵, Manuel Díaz-Llopis¹⁶, Roberto Gallego¹⁶, Miguel Cordero¹⁷, Francisco Ortiz-Sanjuán¹, Joaquín Cañal Villanueva¹⁸, Leyre Riancho-Zarrabeitia¹ and Miguel A González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ³Autoimmune Disease Unit, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ⁴Ophthalmology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ⁵Ophthalmology, Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, ⁶Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁷Rheumatology, Hospital Dr. Peset. Valencia. Spain, Valencia, Spain, ⁸Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, ⁹Ophthalmology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, ¹⁰Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ¹¹Rheumatology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, ¹²Ophthalmology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, ¹³Rheumatology, Hospital Infanta Sofía. San Sebastián de los Reyes. Spain, Madrid, Spain, ¹⁴Ophthalmology, Hospital Infanta Sofía. San Sebastián de los Reyes. Spain, Madrid, Spain, ¹⁵Rheumatology, Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ¹⁶Ophthalmology, Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ¹⁷Ophthalmology, Hospital de León. Spain, León, Spain, ¹⁸Ophthalmology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Intravenous methylprednisolone pulse therapy in severe inflammatory eye disease. A Multicenter Study.Background/Purpose Treatment with high-dose intravenous methylprednisolone (IVMP) pulse therapy has proved to be effective…
Abstract Number: 2318 • 2013 ACR/ARHP Annual Meeting
Disease Activity in Moderate and Severe Rheumatoid Arthritis At Discontinuation in 10-Year Open-Label Extension Studies With Etanercept
Michael E. Weinblatt¹, Joan M. Bathon², Michele Hooper³, Bojena Bitman⁴, Yue Yang⁵, David H. Collier⁶, James Chung⁷ and Mark C. Genovese⁸, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Amgen Global Safety, Amgen Inc., Thousand Oaks, CA, ⁴Amgen, Inc., San Francisco, CA, ⁵Assent Consulting, South San Francisco, CA, ⁶Amgen Inc., Thousand Oaks, CA, ⁷Amgen, Thousand Oaks, CA, ⁸Division of Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Retention rates may be used as a surrogate of long-term effectiveness of drug therapy in open-label studies. Studies have reported that patients (pts)…
Abstract Number: 1052 • 2013 ACR/ARHP Annual Meeting
Glucocorticosteroids and Mortality Risk In Rheumatoid Arthritis – Results Of a Population Based Study
Diane Lacaille¹, J. Antonio Avina-Zubieta^2,3, Eric C. Sayre², Michal Abrahamowicz⁴ and John Esdaile^1,5, ¹Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁵Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Glucocorticosteroids (GC) are frequently used in the management of rheumatoid arthritis (RA). Due to their metabolic and immunosuppressive effects, they could increase the risk…
Abstract Number: 1007 • 2013 ACR/ARHP Annual Meeting
Dose Of Corticosteroid, Risk Of Adverse Events and Healthcare Resource Utilization In Systemic Lupus Erythematosus
Wei-Shi Yeh¹, Shih-Yin Chen², Kathleen McCarty³, Qian Li², Yuan-Chi Lee² and Nathalie Franchimont³, ¹Biogen Idec, Cambridge, MA, ²United BioSource Corporation, Lexington, MA, ³Biogen Idec Inc., Weston, MA
Background/Purpose: Gluco-corticosteroids (GCs) are frequently used to treat autoimmune disease and their chronic use has long been known to cause adverse events (AEs). The purpose…
Abstract Number: 184 • 2012 ACR/ARHP Annual Meeting
The Retrospective Review of 39 Intestinal Behcet’s Disease Focusing On the Requirement for the Immunosuppresive Drugs Other Than Corticosteroid
Yoshitaka Kimura¹, Kurumi Asako², Hirotoshi Kikuchi², Akiteru Takeuchi³ and Hajime Kono², ¹Department of Internal Medicine, Teikyo University school of medecine, Tokyo, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³6-7-8 Arakawa, Tokyo, Japan
Background/Purpose: To examine the demography, clinical characteristics, features of intestinal lesions, treatment, and prognosis in patients with the intestinal Behcet’s disease currently followed at a…
Abstract Number: 98 • 2012 ACR/ARHP Annual Meeting
How to Assess Risks for Pulmonary Infection in Patients Receiving Immunosuppressive Treatment for Rheumatic Diseases? A Report From a Large-Scale Prospective Cohort Study
Hayato Yamazaki¹, Ryoko Sakai¹, Ryuji Koike², Yasunari Miyazaki³, Michi Tanaka¹, Toshihiro Nanki¹, Kaori Watanabe¹, Shinsuke Yasuda⁴, Takashi Kurita⁵, Yuko Kaneko⁶, Yoshiya Tanaka⁷, Yasuhiko Nishioka⁸, Yoshinari Takasaki⁹, Kenji Nagasaka¹⁰, Koichi Amano¹¹, Shigeto Tohma¹², Makoto Dohi¹³, Takahiko Sugihara¹⁴, Haruhito Sugiyama¹⁵, Yasushi Kawaguchi¹⁶, Naohiko Inase¹⁷, Sae Ochi¹⁸, Hiroyuki Hagiyama¹⁹, Nobuyuki Miyasaka²⁰ and Masayoshi Harigai²¹, ¹Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ²Clinical Research Center, Tokyo Medical and Dental University, Tokyo, Japan, ³Department of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁵Department of Medicine II, Hokkaido University, Sapporo, Japan, ⁶Dept of Internal Medicine, Keio Univ School of Medicine, Tokyo, Japan, ⁷The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁸Department of Respiratory Medicine & Rheumotology, The Univeristy of Tokushima Graduate School, Tokushima, Japan, ⁹Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ¹⁰Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ¹¹Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ¹²Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, ¹³Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ¹⁴Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ¹⁵Division of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan, ¹⁶Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁷Dept of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁸Department of Rheumatology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan, ¹⁹Department of Rheumatology, Yokohama-city Bay Red Cross Hospital, Yokohama, Japan, ²⁰Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ²¹Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Patients with rheumatic diseases given immunosuppressive therapy are susceptible to various types of infections, especially pulmonary infections that affect their vital prognosis. The aim…
Abstract Number: 1139 • 2012 ACR/ARHP Annual Meeting
Inhaled Nitrous Oxide Facilitates Access to Intra-Articular Corticosteroid Injections in Children with Juvenile Idiopathic Arthritis
Mercedes O. Chan¹, Ruth Wyllie² and H. E. Foster³, ¹Department of Pediatrics, Division of Pediatric Rheumatology, University of British Columbia and British Columbia's Children's Hospital, Vancouver, BC, Canada, ²Paediatric Rheumatology, Newcastle Hospitals, NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom, ³Paediatric Rheumatology, Newcastle Hospitals NHS Foundation Trust, Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood affecting 1 in 1000 children. Medical management for arthritis often includes intra-articular…
Abstract Number: 1656 • 2012 ACR/ARHP Annual Meeting
Treatment of Systemic Necrotizing Vasculitides in Patients ≥65 Years Old: Results of the Multicenter Randomized Cortage Trial
Christian Pagnoux¹, Thomas Quemeneur², Jacques Ninet³, Elodie Perrodeau⁴, Elizabeth Diot⁵, Xavier Kyndt⁶, Benoit de Wazières⁷, jean-Luc Reny⁸, Xavier Puéchal⁹, Pierre-Yves Leberruyer¹⁰, Olivier Lidove¹¹, Philippe Vanhille¹², Pascal Godmer¹³, Aimé Albath-Sadiki¹⁴, Boris Bienvenu¹⁵, Pascal Cohen¹⁶, Luc Mouthon¹⁷, Philippe Ravaud⁴, Loic Guillevin¹⁸ and French Vasculitis Study Group (FVSG)¹⁹, ¹Internal Medicine, Department of Internal Medicine, National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Université Paris – Descartes, Paris, France, Paris, France, ²Internal medicine, CHR de Valenciennes, Valenciennes, France, ³Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ⁴Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁵Department of Internal Medicine, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France, Tours, France, ⁶Department of Nephrology and Internal Medicine, CH, Valenciennes, Valenciennes, France, ⁷Department of Internal Medicine and Gerontology, Hôpital Universitaire Carémeau, Nîmes, France, Nimes, France, ⁸Service de médecine interne générale Hôpitaux universitaires de Genève, Geneve, Switzerland, ⁹National Referral Center for Rare Systemic Auto-immune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ¹⁰Hôpital Robert Debré, Centre Hospitalier Universitaire de Reims, Reims, France, Reims, France, ¹¹Médecine interne, Hôpital Croix-Saint-Simon, PARIS, France, ¹²Department of Nephrology and Internal Medicine, Hospital of Valenciennes, Valenciennes, France, Valenciennes, France, ¹³Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ¹⁴Urc, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, 27 rue du faubourg Saint Jacques, Paris, 75014, France, Paris, France, ¹⁵Médecine interne, CHU Côte de Nacre, CAEN, France, ¹⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹⁷Internal Medicine, Hopital Cochin, Paris, France, ¹⁸Internal Medicine, Cochin University Hospital, Paris, France, ¹⁹Department of Internal Medicine, National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Université Paris – Descartes, Paris, France
Background/Purpose: To optimize the therapeutic strategy for the elderly with systemic necrotizing vasculitides (SNV; polyarteritis nodosa (PAN), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) or…